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The Pistoia Alliance Controlled
Substance Compliance Service Project:
from start to finish
Daniel Taylor1, Stuart G. Bowden2, Reinhard Knorr3, Derek R. Wilson4, John Proudfoot5 and
Anne E. Dunlop6, Anne.Dunlop@PistoiaAlliance.org
Pharmaceutical companies and other life science R&D organizations routinely work with controlled
substances, and must have adequate controls in place to meet the legislative requirements of the
countries in which they operate. Controlled substances include a range of narcotics and psychotropic
drugs, which are covered by increasingly complex legislation as legislators attempt to keep up with a
rapidly changing environment. This legislation must be interpreted and transformed from legal wording
into chemical structures to be used effectively. Over the past year a working party of pharmaceutical and
technology companies has come together under the umbrella of the Pistoia Alliance to define a
Controlled Substance Compliance Service. We describe the benefits of bringing together this group of
experts to solve the pre-competitive issue of controlled substance management.
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Pharmaceutical companies and other life science
R&D organizations routinely work with controlled
substances. Rigorous controls must be imple-
mented to meet the legislative requirements of
the countries in which the companies operate. For
example, many institutions and pharmaceutical
companies conduct research aimed at increasing
our understanding of the central nervous system
and are developing treatments for conditions
such as Schizophrenia, Depression, Alzheimer’s
disease and Parkinson’s disease. In this context, a
broad range of pharmacologically active sub-
stances, including controlled substances, are used
as reference standards.
Controlled substances include a range of drug
precursors, narcotics and psychotropic drugs,1359-6446/06/$ - see front matter 2014 The Authors. Published by E
http://dx.doi.org/10.1016/j.drudis.2014.09.021 which are covered by increasingly complex
legislation as legislators attempt to keep up with
a rapidly changing environment [1]. Legislation
exists at local, national and international levels
[2] to restrict the production, import and export,
supply, use and possession of these substances.
Substances can be temporarily controlled; for
example, in the USA the Drug Enforcement
Administration (DEA) can temporarily place
drugs in Schedule I status pending permanent
placement in Schedule I or letting the scheduling
lapse. Organizations must continuously monitor
legislation to ensure they can identify any newly
scheduled substances. The interpretation of the
US Federal Analog Act is particularly challenging
because the definition of analog is deliberately
vague and broad. For R&D organizations to belsevier Ltd. This is an open access article under the CC BY-NC-SA licenseable to comply with this legislation effectively, the
legislation must be interpreted and transformed
from legal wording into scientific nomenclature
(i.e. words into chemical structures). Lists of
controlled substances are often published in the
legislation in non-systematic formats; it is a
challenge for research scientists to identify them,
quickly and accurately, to remain compliant with
legislation. For example, during the course of this
project we had the opportunity to compare dif-
ferent team members’ translations of these con-
trolled substance lists into chemical structures
and we found some subtle differences.
The increasing externalization and globalization
of the pharmaceutical industry means substances
are routinely produced, stored and transported
across national borders and legislative domains, (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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need to have a clear, detailed and accurate un-
derstanding of the regulations in all the regions in
which they operate. Controlled drug legislation
develops country by country in different time-
scales; it is controversial [3–6], complex and ever
changing as it tries to keep ahead of substance
abuse and trends in the manufacture of so-called
‘legal highs’ [7–10]. It is this ever changing nature
and broad interpretive basis of the controlled drug
legislation that causes the greatest challenges for
pharmaceutical companies to keep their large and
diverse compound libraries in compliance. The
risks to an organization of noncompliance with
controlled substance regulations are real and
substantial, not only in terms of fines and revo-
cation of licenses but also loss of reputation. There
are a number of well documented examples
where organizations have faced significant pen-
alties for failing to comply with the US Controlled
Substances Act (http://www.justice.gov/dea/divi-
sions/mia/2013/mia061113.shtml; http://
www.justice.gov/dea/divisions/hq/2013/
hq040313.shtml; http://www.justice.gov/dea/
divisions/nj/2013/nj102313.shtml).
The Pistoia Alliance is a not-for-profit, multi-
company members’ organization committed to
lowering the barriers to innovation in life science
R&D. It achieves this aim by improving the
interoperability of R&D business processes
through precompetitive collaboration. It draws its
membership from pharmaceutical R&D and other
life science R&D organizations, commercial in-
formation providers, technology companies and
other publically funded research organizations.
The Pistoia Alliance brings together the key sta-
keholders to identify the root causes of R&D
inefficiencies; then it develops best practiceCSCS project
starts
2012 
FIGURE 1
Project timeline showing key controlled substance co
176 www.drugdiscoverytoday.comrecommendations and technology implementa-
tions to overcome common obstacles. The con-
sistent identification of controlled substances in
databases and sample collections was identified
as a precompetitive challenge that is common to
many life science organizations and this challenge
requires a collaborative, cross-industry resolution.
Pre-project background
The Pistoia Alliance hosted a meeting between
representatives from the GlaxoSmithKline and
AstraZeneca compound management groups to
identify opportunities for precompetitive col-
laboration within the domains of screening,
compound handling and logistics. From the
enthusiastic discussions at this meeting, the
common challenge of controlled substance
legislation interpretation quickly emerged. The
outcome of these discussions was recognition
that no commercially available solutions
addressed the requirements of the work group
members. Furthermore, each individual life sci-
ence organization that works with controlled
substances must replicate the effort and ex-
penditure on monitoring legislation and con-
trolled substance compliance activities.
It was apparent that many organizations had
developed custom-built in-house solutions to
ensure compliance with legislative requirements
for controlled substances. It was estimated that
the potential savings to the industry of imple-
menting a controlled substance compliance
service (CSCS) solution were in the region of
US$90 million.
Project process
The topic of CSCS fell within the remit of pre-
competitive, cross-company, collaborative openUser acceptance
testing (UAT) of
CSCS
implementations
completed
CSCS
requirements
gathering and
RFP publications
2 Vendors
contracted
CSCS
implementati
demonstratio
webinar
2013 2014
mpliance service (CSCS) project milestones. Abbreviatinnovation and, as such, was amenable to the
Pistoia Alliance project process (Fig. 1). A clear
business case for the project was generated and
gained approval from the Pistoia Alliance board.
The Pistoia Alliance extensive industry network
was polled to solicit broader participation in the
project.
The Pistoia Alliance proposed the use of a
shared-risk funding model, where pharma
project members each contributed to fund the
project and, as such, formed the project steering
committee. Representatives from the funding
companies established a steering committee
that would oversee the project and its finances.
In addition, an international project team (IPT)
was formed consisting of experts from phar-
maceutical company chemistry and materials
management, and from technology companies
that specialize in chemoinformatics. The teams
were supported by a Pistoia Alliance contracted
project manager. Having representatives from
pharmaceutical and technology companies
present during the early project discussions was
crucial for developing strong connections with,
and across, the IPT and steering committee. This
approach gave the technology suppliers a good
understanding of the customers’ requirements
and an early indication of the potential com-
mercial opportunities for a solution.
Requirements analysis
The first task was to define the scope of the term
‘controlled substance’. Early discussions revealed
that this term had different meanings among the
team members. Controlled drugs, chemical
weapons and ozone-depleting substances were
among examples offered. However, the discus-
sions eventually focused on controlled drugson
n
CSCS
implementations
commercially
available
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ion: RFP, request for proposal.
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FIGURE 2
Examples of controlled substance structures.
Fe
at
u
re
s
 P
E
R
S
P
E
C
T
IV
Eand their precursors. Owing to the complexity of
the legislation of controlled drugs, a compliance
solution in this area would provide a strong
foundation toward addressing subsequent leg-
islation. Controlled drugs fall within regional,
national and international legislation that reg-
ulates their whole lifecycle use including storage,
handling, shipping and destruction or disposal.
The legislation can apply controls to specific
drugs such as morphine, cocaine, LSD and ec-
stasy but can also apply to a broad set of analogs
or derivatives of a parent structure, for example
methcathinones and phenethylamines (Fig. 2).
A key benefit of working in a cross-pharma
project team under the umbrella of the Pistoia
Alliance was building a shared understanding of
the current compliance practices within each
company, where their strengths lay and where
the common ‘pain points’ were in terms of
efforts to stay in compliance. It was also ex-
tremely valuable to discuss different approaches
to legislative interpretation and how each
company interacted with the regulatory bodies.
Recognizing that there could be benefits to the
international regulatory bodies from this shared
and consistent approach, the Pistoia Alliance
reached out to the International Narcotics Con-
trol Board (INCB) and the UK Home Office to
obtain clarification on a number of queries that
the project team had identified. The UK Home
Office confirmed that parahexyl is controlled in
the UK under Schedule 1 and the INCB provided
guidance on the definition of ‘isomers’. In gen-
eral, the agencies were supportive of the ap-
proach and could see benefits in the tool.
Indeed, one regulatory agency contacted the
Pistoia Alliance for comments in advance of new
drug legislation concerning NBOMe (variant of
phenethylamine) and benzofuryl analogs, which
were being offered for sale as legal highs(https://www.gov.uk/government/uploads/sys-
tem/uploads/attachment_data/file/261786/
NBOMe_compounds_report.pdf ).
Discussions revealed a desired future state
encompassing either a database or an expert
system as the basis of the solution. Initially there
was a strong preference toward a database-
driven system of curated lists of controlled
molecular structures. As discussions progressed
and the IPT started to understand the breadth
and complexity of controlled substance legisla-
tion, it became clear that a database approach
would not provide a satisfactory solution.
A key user requirement was the capacity to
screen many millions of chemical structures ef-
ficiently against the controlled chemical legis-
lation. There was a realization that
comprehensive enumeration of the broad
structural families covered in legislation would
be prohibitive. For example, there are theoreti-
cally an infinite number of phenethylamine
analogs, because alkyl and acyl side-chain length
is not limited. Discussions moved toward expert
systems that could apply chemoinformatics
searching against Markush-like rules, asking
questions of the datasets rather than comparing
exact structures against database lists.
Detailed market research revealed no off-the-
shelf solutions that met the intended scope of
legislative coverage, although AstraZeneca did
have an internal tool that had been adapted for
controlled substance searching [11]. AstraZe-
neca shared this tool with the team, which
provided an understanding of how the searches
worked as well as a vision of what could be
achieved. A limitation AstraZeneca had identi-
fied was the ongoing maintenance of their
system, given the specialized nature of identi-
fication, interpretation and keeping up-to-date
with relevant controlled substance legislation.This opened discussions on the expertise re-
quired of a potential vendor (e.g. software de-
velopment, cheminformatics knowledge and
chemically aware legal capability). Through
these very open discussions between project
members, a clear and shared future state was
described.
Future state
Use cases were developed, then prioritized using
the MoSCoW (must, should, could, will not)
methodology and a detailed set of functional
and nonfunctional requirements were agreed
and documented. These requirements enabled
the compilation of a request for proposal (RFP).
Because of time constraints, it was initially de-
cided to split the project into a number of
phases. The key deliverables of the first phase of
the CSCS project were identified as a Legislation
Notification Service, a Legislation Knowledge-
base and an Expert System. The Legislation
Notification Service would send out details of
new, updated and clarified legislation to the
service customers. The Legislation Knowledge-
base covering North America and Europe would
include interpretation of the legislation and
detailed guidance information for impacted
substances. The Expert System would determine
whether a substance was controlled or not using
a set of rules and structures derived from the
legislation. To ensure the security of a customer’s
internal compound collection, the CSCS system
architecture would need to support implemen-
tation inside the customer’s firewall and would
need to interface to the customer’s internal
chemistry systems.
Request for proposal
The RFP was advertised on the Pistoia Alliance
and the RSC Chemistry Weekly websites, and thewww.drugdiscoverytoday.com 177
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vidual qualified technology company contacts
were made aware of this document. The aim was
to select up to three competing vendors, each
producing their own software solution, with the
rationale that this: (i) allowed customers some
choice in selecting the product that met their
particular needs; (ii) would keep costs compet-
itive; and (iii) would mitigate the risk that a single
vendor could fail to satisfy the project require-
ments. In total, 41 companies responded to an
invitation to a webinar where the project was
outlined and the RFP explained. It transpired that
companies required a mixed skill set to imple-
ment this project: experience in the creation of
chemical databases and retrieval applications as
well as expertise in the interpretation of the
different controlled substance legislations.
Shortlisted vendors were then invited to
present their proposed solutions to the project
team. These presentations were assessed against
pre-defined criteria and three preferred vendors
were selected to progress to contract negotia-
tions. It was noted at this stage that, although
vendors presented individual proposals, a
number of those proposals represented vendor
partnerships where individual vendors had
some, but not all, of the expertise to deliver the
solution.
System build
Following the final selection of the two suc-
cessful proposals, one by ChemAxon and Patcore
with their Compliance Checker system and the
other by Scitegrity with its CS2 system, devel-
opment was initiated. This phase of the project
revealed the strength of the Pistoia Alliance
shared-risk funding model. The vendors effec-USA
UK
CH
100500
FIGURE 3
Test dataset substance controlled status in the USA, U
178 www.drugdiscoverytoday.comtively became fully integrated project members.
Regular feedback meetings were held as a whole
group, facilitating open discussions to enable
vendors to understand precisely the customer
requirements. Vendors were also able to reflect
back to the project team the options and chal-
lenges they were facing in building the systems,
allowing the most appropriate solutions to be
progressed at a greater pace.
Testing and evaluation
Data quality and predictive accuracy were the
critical quality factors required by the pharma
team members for any CSCS solution. For this
reason the team focused on compiling a test
dataset of over 400 structures to assess the
performance of the vendors’ systems. The
dataset contained controlled and non-controlled
structures across a range of chemical classes and
legislative schedules, and was provided to the
vendors in the SD and SMILES chemistry data file
formats. In addition to well recognized con-
trolled substances, the dataset also included
substances close to the boundaries of what
would be considered controlled or not con-
trolled, including examples that were known to
be contentious.
We chose to build the test dataset from a
subset of the phase 1 countries, which were of
most importance to the project team members.
Combining datasets from different countries to
create a comprehensive dataset was challeng-
ing. The different legislative approaches of each
test country resulted in significant differences in
the controlled status of the individual test sub-
stances, across the test countries (Fig. 3). As a
result, a particularly difficult aspect of this task
was reaching agreement on whether or not350300250200
Test substances ID number
150
K and Switzerland (CH).specific examples in the dataset were controlled.
A challenging example was the interpretation of
the US Controlled Substance Act Schedule III for
derivatives of barbituric acid; did the US DEA
mean 5,5-disubstituted derivatives (as per the UK
regulations) or should 5,5-disubstituted barbi-
turates only be flagged as US controlled sub-
stances if they appear on the official lists (Table
1)? It was noted that the majority of the chal-
lenges faced by the vendors were not IT related
but rather the interpretation of legislation. The
Pistoia Alliance network has been working
actively to open lines of communication to
legislative bodies to help clarify more ambiguous
interpretations.
As part of the shared-risk funding model, the
phased release of funding was triggered on
reaching pre-agreed milestones and evaluation of
system performance against pre-defined data-
sets. These test datasets were challenging, they
contained chemicals that fell close to and across
the borderlines of legislative criteria, demanding
highly refined computational tools to find the
correct answer. In addition to the test datasets,
user acceptance testing was carried out on the
systems according to the criteria documented
within the use cases developed earlier in the
project. Again, this provided open and honest
feedback on the suitability and usability of the
systems, allowing vendors to refine their tools
further. The vendors then applied their systems to
identify the controlled status of chemical struc-
tures with reference to legislation from the USA,
UK, Switzerland, France, Sweden and Canada. In
each of these countries a different approach has
been taken to define controlled substances, but
companies’ expert systems were able to classify
these test structures with high accuracy. Final400
Not controlled
Legend
Controlled
May be controlled
Drug Discovery Today 
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TABLE 1
Examples of controlled status of barbituric acids in the USA, UK and Switzerland
Substance USA UK Switzerland
Pentobarbital US Controlled
Substance Act
Schedule II
Misuse of Drugs
Act Schedule 3
Swiss Controlled
Substances Act
(BetmVV-EDI)
Narcotics List B
5-Methyl-5-(1-methylethenyl)-
2,4,6(1H,3H,5H)-pyrimidinetrione
Can be controlled Misuse of Drugs
Act Schedule 3
Markush
Any 5,5 disubstituted
barbituric acid
Not controlled
Hexahydro-1,3-dicyclohexyl-alpha-
methyl-2,4,6-trioxo-
5-pyrimidineacetic acid
Can be controlled Not controlled Not controlled
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vendors. The 1% disagreement related mainly to
differences in interpretation of the legislation,
where the vendors took a conservative approach
and flagged substances as controlled. Through-
out vendor system development, the Pistoia Al-
liance project team provided continuous
feedback, support, direction and advice to the
vendors.
System demonstration and
commercialization
The final versions of both systems were dem-
onstrated via webinar to a broad group of po-
tential users, including major pharmaceutical
and technology companies. The Pistoia Alliance
promotes customer choice and both systems are
now commercially available for potential cus-
tomers to evaluate against their own internal
criteria.
Compliance Checker is a software system and
content package developed by Patcore and
ChemAxon. Based on ChemAxon’s JChem tech-
nology for structure entry and representation (a
well trusted industry-leading cheminformatics
platform for over 16 years), Compliance Checker
allows users to perform controlled substance
checks by either chemical structures (through
the drawing functionalities of Marvin) or by text,
CAS numbers, SMILES strings, IUPAC names oreven by common names. Checks can be per-
formed with either individual structures (input-
ted via Marvin) or as a large set of structures
stored in SD or text files. Compliance Checker
has a variety of interfaces for different user types
and can be integrated with workflow tools like
KNIME and Pipeline Pilot, ELN, registration or
reagent management systems via web service
access or command line. Compliance Checker is
available as a web- or client-based system for
bench access with Microsoft Office (Excel, Word),
HTML and PDF output and its deployment is
straightforward [12]. Compliance Checker relies
on an up-to-date and extensive knowledgebase
made up of relevant published legislations
covering most of the North American, European
and Asian countries. The software and legislation
databases are created and maintained by Pat-
core in close collaboration with ChemAxon.
The Scitegrity Controlled Substances Squared
(CS2) system is a completely new system built
specifically to the Pistoia CSCS requirements
using tried and trusted, industry-leading core
software from Biovia (formerly Accelrys), namely
Pipeline Pilot and the Accelrys Direct chemistry
cartridge for Oracle. These Biovia products are
well known in the pharmaceutical industry and
are proven to have the ability to be integrated
quickly and efficiently into a company’s existing
IT infrastructure. This means that CS2 can becalled at many levels within an organization,
ranging from an intuitive web browser front end,
through API integration with existing applica-
tions such as electronic laboratory notebooks,
materials management tools and chemistry
synthesis design tools, to the storage of con-
trolled status of complete corporate collections
for almost instantaneous retrieval. All controlled
substance hits are accompanied with a wealth of
supporting material concerning the underlying
legislation with, additionally, the ability for the
customer to add their own company-specific
guidance.
Concluding remarks
This project has demonstrated the benefits of
precompetitive, cross-company collaboration.
Shared knowledge and expertise, open discus-
sion and joint funding led to a faster and more-
comprehensive set of requirements. Importantly,
technology supplier involvement in the project
at the earliest opportunity made for a dialog and
ensured a good two-way understanding of
business needs and technology feasibility, and
easier implementation of the software solutions.
The project team has also formed a close bond
through trust built up over many months. The
positive experience has been relayed back into
each pharmaceutical company, making it easier
in the future to pursue further cross-companywww.drugdiscoverytoday.com 179
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intercompany collaboration continue to gather
pace, the notion of exchanging or sharing
compound libraries is becoming a reality. Use of
a common controlled substance compliance
system will help to ensure a common process in
identification of such compounds, thus avoiding
potential future problems.
This phase of the CSCS project focused on the
legislative regions that were of most importance
to the project team. But, given the growing
externalization and outsourcing within the
pharmaceutical industry, legislation from other
countries including China and India needs to be
included in future releases. Following discus-
sions with the project team, it was agreed that
the choice of extra legislative regions was a
commercial decision to be made by a vendor
based on the requirements of their customers.
The legislative environment is constantly
changing, new pieces of legislation are brought
into force and existing legislation can be
updated or clarified. It takes significant amounts
of time and expertise to monitor and interpret
the legislation. The key benefit of the legislation
notification service is that it will free-up the
individual CSCS customers from the time and
effort of monitoring their legislative areas of
interest. A vendor would provide this service to
all their customers.
Although the project team is confident in the
implementation of the chemoinformatics and
the technology supplied by the vendors, it is
limited by the interpretation of the legislation to
generate the rules utilized by these expert sys-
tems. The regulatory authorities can sometimes
appear reluctant to provide guidance on specific
areas of their legislation. The team found value in
bringing together experts from across the world
to review the sometimes ambiguous and often
difficult-to-interpret legislation. The Pistoia Alli-
ance believes that there would be real benefit in
providing a harmonized analysis and interpre-
tation from a group of industry experts. The180 www.drugdiscoverytoday.comCSCS project now aims to create an industry-
leading, CSCS expert community (http://
www.cscs-experts.org). Such an organization
would provide support to continue the work of
this group of experts while improving the un-
derstanding and interpretation of controlled
substance legislation from around the world. The
project team believes that there are real benefits
to be derived from standardized legislative in-
terpretation.
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